Atopic Dermatitis: Ruxolitinib And Baricitinib Spearheading New Therapies
Wave Of New Treatments Expected Over The Next Few Years.
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
